Provided by Tiger Fintech (Singapore) Pte. Ltd.

Olema Pharmaceuticals, Inc.

4.14
-0.3100-6.97%
Post-market: 4.140.00000.00%16:05 EDT
Volume:482.70K
Turnover:2.01M
Market Cap:307.20M
PE:-1.81
High:4.36
Open:4.36
Low:4.09
Close:4.45
Loading ...

Company Profile

Company Name:
Olema Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
88
Office Location:
780 Brannan Street,San Francisco,California,United States
Zip Code:
94103
Fax:
- -
Introduction:
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Directors

Name
Position
Sean Bohen
President, Chief Executive Officer and Director
Cyrus L. Harmon
Chief Technology Officer and Director
Ian Clark
Chairperson of the Board of Director
Andrew Rappaport
Director
Cynthia Butitta
Director
Frank McCormick
Director
Gorjan Hrustanovic
Director
Graham Walmsley
Director
Sandra Horning
Director

Shareholders

Name
Position
Sean Bohen
President, Chief Executive Officer and Director
Cyrus L. Harmon
Chief Technology Officer and Director
David C. Myles
Chief Development Officer
John B. Moriarty, Jr.
Executive Vice President, Chief Legal Officer and Corporate Secretary
Kinney Horn
Chief Business Officer
Peter J. Kushner
Chief Scientific Officer
Shane Kovacs
Chief Operating and Financial Officer